Scleroderma research starts with you. Learn more to find out if enrolling in the CONQUER registry is right for you! In 2018, the SRF launched the CONQUER Registry—a first-of-its-kind nationwide...
Read More
Turning hope into action begins with a strategic approach to funding scleroderma research. When it comes to our core research portfolio, our Scientific Advisory Board, made up of some of...
Read More
Since 1987, this dedicated community has stood shoulder to shoulder with the SRF, helping to drive research toward a cure for scleroderma. Because of your generosity and commitment, 2024 was...
Read More
We are honored to announce that CONQUER has enrolled its 1,000th participant! 🎉 In 2018, the SRF launched the CONQUER Registry (an acronym for COllaborative National QUality and Efficacy Registry)—a first-of-its-kind nationwide…
Here at the Scleroderma Research Foundation, research is at the center of all we do to find a cure—and that's only possible because of the dedicated support of our community....
Read More
Research is at the center of all we do here at the SRF to find a cure for scleroderma. This is why, in 2018, we launched CONQUER (COllaborative, National QUality...
Read More
In 2018, the SRF launched the CONQUER Registry (COllaborative National Quality and Efficacy Registry) – a first-of-its-kind longitudinal, nationwide patient registry and biosample repository aimed at improving care and developing...
Read More
"I lost a lot of me." This is what Cynthia, dx 2021, shared about living with scleroderma. It's just one of many reasons why she participates in research that accelerates...
Read More
Join us in welcoming the University of California, Los Angeles to the CONQUER Registry! UCLA recently joined the CONQUER Registry—a highly collaborative consortium of some of the largest scleroderma centers…
Last week during the American College of Rheumatology Conference in Philadelphia, the SRF hosted two meetings to convene Principal Investigators and Research Coordinators from all 17 institutions participating in the…
